3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase NA
1
Phase 4
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
4
NET
2
Conditions
Neuroendocrine Tumors
32
Gastro-enteropancreatic neuroendocrine tumor
6
Carcinoid Tumor
4
Adenoma, Islet Cell
3
Serotonin Syndrome
2
Parkinson Disease
2
Neuroblastoma
2
Neoplasms
2
Congenital Hyperinsulinism
2
Advanced Gastroenteropancreatic Neuroendocrine Tumor
2
Thymus Neoplasms
1
Pancreatic Neuroendocrine Tumors in MEN1
1
Pancreatic Neuroendocrine Tumors (pNET)
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors in Lung
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
1
Lymphoma, Follicular
1
Liposarcoma
1
Lewy Body Disease
1
Insulinoma
1
Hypoglycemia
1
Hyperinsulinism
1
Flushing
1
Fibrosarcoma
1
Disease
1
Digestive Neuroendocrine Tumors
1
Diarrhea
1
Carcinoid Tumors, Intestinal
1
Interventions
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Serotonin Syndrome
×
NET
×
Clear all
NCT07087054
2026-04-30
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3
Recruiting
141 enrolled
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts